Merck and Ridgeback's Molnupiravir, an Investigational Oral Antiviral COVID-19 Treatment, Receives Special Approval for Emergency in Japan Pharmaceutical Investing
Lifshitz Law Firm, P.C. Announces Investigations of Bristol-Myers Squibb Company , Eargo, Inc. , Hyzon Motors Inc. , Nano-X Imaging Ltd. , and View, Inc. Pharmaceutical Investing
Merck and Ridgeback's Molnupiravir Receives U.S. FDA Emergency Use Authorization for the Treatment of High-Risk Adults With Mild to Moderate COVID-19 Pharmaceutical Investing
Gilead Announces New England Journal of Medicine Publication of Data Demonstrating Veklury® Significantly Reduced Risk of Hospitalization in High-Risk Patients With COVID-19 Pharmaceutical Investing
Numinus Wellness Commends Health Canada on Special Access Programme Amendments to Restore Potential Access to Psychedelic Medicines Pharmaceutical Investing
Pfizer Receives U.S. FDA Emergency Use Authorization for Novel COVID-19 Oral Antiviral Treatment Pharmaceutical Investing
BetterLife's Wholly-Owned Subsidiary, Altum Pharmaceuticals, Obtains Non-Dilutive Financing Commitment From Strategic Investor! Pharmaceutical Investing
Merck and Ridgeback Announce U.K. Government to Purchase Additional 1.75 Million Courses of Molnupiravir Pharmaceutical Investing
